Global Bipolar Disorder Treatment Market - 2025-2033
Overview
The global bipolar disorder treatment market size reached US$ 5.80 billion in 2024 and is expected to reach US$ 9.75 billion by 2033, growing at a CAGR of 6.0% during the forecast period 2025-2033.
Bipolar disorder is a mental health condition characterized by extreme mood swings, ranging from manic or hypomanic episodes to depressive episodes. These mood swings can significantly impact an individual's daily life and overall functioning. There are different types of bipolar disorder, including Bipolar I and Bipolar II, which are distinguished by the severity and duration of manic and depressive episodes.
Treatment for bipolar disorder typically involves a combination of medication and psychotherapy. Mood stabilizers, such as lithium, are commonly used to manage manic episodes, while antidepressants or antipsychotic drugs are often prescribed to address depressive symptoms. Cognitive behavioral therapy (CBT) and other forms of psychotherapy can also play an important role in helping individuals manage their symptoms, develop coping strategies, and improve emotional regulation.
Market Dynamics: Drivers & Restraints
Increased Research and Development (R&D)
Increased research and development (R&D) in the bipolar disorder treatment market is expected to drive significant progress in the development of more effective and targeted therapies. As scientists gain a deeper understanding of the complex genetic, biological, and environmental factors contributing to bipolar disorder, new treatment strategies are emerging. These advancements aim to target the underlying causes of the disorder more precisely, which could lead to medications that offer better symptom control with fewer side effects.
R&D is also crucial in the shift towards personalized medicine, where treatments are tailored to a patient’s specific genetic profile and how they respond to certain therapies. The bipolar disorder treatment landscape is experiencing a surge in research and development, as evidenced by recent clinical trial advancements from leading biopharmaceutical companies. For instance, on September 16, 2024, Autobahn Therapeutics announced the initiation of AMPLIFY, a Phase 2 clinical trial evaluating ABX-002 as an adjunctive treatment for adults with major depressive disorder (MDD). ABX-002, a thyroid hormone beta receptor (TR?) selective agonist, is designed to improve CNS efficacy and safety, representing a novel mechanism of action in the broader neuropsychiatric space.
Similarly, on November 12, 2024, BioXcel Therapeutics reported significant progress in its pivotal Phase 3 trials for BXCL501, a sublingual film being developed for the acute treatment of agitation in patients with bipolar disorders, schizophrenia (SERENITY At-Home), and Alzheimer’s dementia (TRANQUILITY In-Care). BXCL501 stands out as there are currently no FDA-approved acute therapies specifically targeting these conditions, highlighting this segment's unmet need and commercial potential.
These developments reflect a broader industry trend toward precision neurotherapeutics and underscore how innovative pipeline therapies and AI-driven drug development are fueling the expansion of the bipolar disorder therapeutics market. As R&D investment continues to rise, more targeted and effective treatments are expected to reach the market, improving outcomes for patients living with mood and cognitive disorders.
Side Effects of Medications
The side effects associated with medications used to treat bipolar disorder pose a significant challenge to the growth of the treatment market. Many of the commonly prescribed drugs, including mood stabilizers, antipsychotics, and antidepressants, come with a range of side effects such as weight gain, drowsiness, cognitive impairment, and metabolic disturbances like diabetes or cardiovascular issues. These adverse effects can severely impact the quality of life for patients, often leading to reduced treatment adherence or even abandonment of therapy.
Segment Analysis
The global bipolar disorder treatment market is segmented based on disorder type, treatment, and region.
Treatment:
The mood stabilizers segment is expected to dominate the bipolar disorder treatment market with the highest market share
The mood stabilizers segment is expected to dominate the bipolar disorder treatment market due to their crucial role in managing the primary symptoms of the disorder, particularly in stabilizing extreme mood swings. Mood stabilizers, such as lithium, valproate, and lamotrigine, are often considered the cornerstone of bipolar disorder treatment because they effectively control both manic and depressive episodes, preventing frequent relapses. Their ability to maintain mood stability over time is essential in reducing the severity and frequency of mood fluctuations, making them a first-line treatment choice for many patients.
As the most established class of medications for bipolar disorder, mood stabilizers are widely prescribed and have a long track record of efficacy. Despite the emergence of newer treatments, the proven effectiveness and ability to provide long-term symptom control make mood stabilizers an essential part of treatment regimens.
Additionally, ongoing research and development in the mood stabilizer category aim to enhance their effectiveness and minimize side effects, further solidifying their dominant position in the market. For instance, in April 2024, Vanda Pharmaceuticals Inc. (Vanda) announced that the U.S. Food and Drug Administration (FDA) had approved Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
Thus, the mood stabilizers segment is expected to continue leading the bipolar disorder treatment market, driven by their central role in managing the core symptoms of the disorder and their widespread use in clinical practice.
Geographical Analysis
North America is expected to hold a significant position in the global bipolar disorder treatment market with the highest market share
North America is expected to maintain a significant position in the global bipolar disorder treatment market, holding the highest market share, due to several important factors. A large number of individuals suffer from bipolar disorder in the region. For instance, according to the report by Mental Health America, an estimated 2.5% of U.S. adults experience bipolar disorder at some time in their lives. The region has a large number of leading pharmaceutical companies and research institutions that are driving innovation in the development of new and more effective treatments for bipolar disorder.
Ongoing research and the introduction of novel therapies, including mood stabilizers, antipsychotics, and antidepressants, continue to improve patient outcomes and address the challenges of side effects, contributing to the growth of the market. For instance, in February 2025, Teva Pharmaceuticals and Medincell announced FDA acceptance of a supplemental New Drug Application for UZEDY, an extended-release injectable for the maintenance treatment of bipolar I disorder in adults—a milestone reflecting the region’s leadership in bringing novel treatment options to market.
Additionally, there is an increasing focus on mental health awareness across North America, leading to more people seeking diagnosis and treatment for bipolar disorder. This shift, combined with the presence of specialized treatment centers and mental health professionals, ensures that patients have access to comprehensive care. As awareness of mental health issues continues to rise and new treatment options emerge, North America is expected to maintain its dominant position in the bipolar disorder treatment market, driving continued growth and adoption of innovative therapies.
Competitive Landscape
Top companies in the bipolar disorder treatment market include AstraZeneca, AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Intra?Cellular Therapies, Inc. (Johnson & Johnson Services, Inc.), Sanofi, Sun Pharmaceutical Industries Ltd., GSK plc, Novartis AG, Pfizer Inc., among others.
Why Purchase the Report?
Target Audience 2024
The global bipolar disorder treatment market size reached US$ 5.80 billion in 2024 and is expected to reach US$ 9.75 billion by 2033, growing at a CAGR of 6.0% during the forecast period 2025-2033.
Bipolar disorder is a mental health condition characterized by extreme mood swings, ranging from manic or hypomanic episodes to depressive episodes. These mood swings can significantly impact an individual's daily life and overall functioning. There are different types of bipolar disorder, including Bipolar I and Bipolar II, which are distinguished by the severity and duration of manic and depressive episodes.
Treatment for bipolar disorder typically involves a combination of medication and psychotherapy. Mood stabilizers, such as lithium, are commonly used to manage manic episodes, while antidepressants or antipsychotic drugs are often prescribed to address depressive symptoms. Cognitive behavioral therapy (CBT) and other forms of psychotherapy can also play an important role in helping individuals manage their symptoms, develop coping strategies, and improve emotional regulation.
Market Dynamics: Drivers & Restraints
Increased Research and Development (R&D)
Increased research and development (R&D) in the bipolar disorder treatment market is expected to drive significant progress in the development of more effective and targeted therapies. As scientists gain a deeper understanding of the complex genetic, biological, and environmental factors contributing to bipolar disorder, new treatment strategies are emerging. These advancements aim to target the underlying causes of the disorder more precisely, which could lead to medications that offer better symptom control with fewer side effects.
R&D is also crucial in the shift towards personalized medicine, where treatments are tailored to a patient’s specific genetic profile and how they respond to certain therapies. The bipolar disorder treatment landscape is experiencing a surge in research and development, as evidenced by recent clinical trial advancements from leading biopharmaceutical companies. For instance, on September 16, 2024, Autobahn Therapeutics announced the initiation of AMPLIFY, a Phase 2 clinical trial evaluating ABX-002 as an adjunctive treatment for adults with major depressive disorder (MDD). ABX-002, a thyroid hormone beta receptor (TR?) selective agonist, is designed to improve CNS efficacy and safety, representing a novel mechanism of action in the broader neuropsychiatric space.
Similarly, on November 12, 2024, BioXcel Therapeutics reported significant progress in its pivotal Phase 3 trials for BXCL501, a sublingual film being developed for the acute treatment of agitation in patients with bipolar disorders, schizophrenia (SERENITY At-Home), and Alzheimer’s dementia (TRANQUILITY In-Care). BXCL501 stands out as there are currently no FDA-approved acute therapies specifically targeting these conditions, highlighting this segment's unmet need and commercial potential.
These developments reflect a broader industry trend toward precision neurotherapeutics and underscore how innovative pipeline therapies and AI-driven drug development are fueling the expansion of the bipolar disorder therapeutics market. As R&D investment continues to rise, more targeted and effective treatments are expected to reach the market, improving outcomes for patients living with mood and cognitive disorders.
Side Effects of Medications
The side effects associated with medications used to treat bipolar disorder pose a significant challenge to the growth of the treatment market. Many of the commonly prescribed drugs, including mood stabilizers, antipsychotics, and antidepressants, come with a range of side effects such as weight gain, drowsiness, cognitive impairment, and metabolic disturbances like diabetes or cardiovascular issues. These adverse effects can severely impact the quality of life for patients, often leading to reduced treatment adherence or even abandonment of therapy.
Segment Analysis
The global bipolar disorder treatment market is segmented based on disorder type, treatment, and region.
Treatment:
The mood stabilizers segment is expected to dominate the bipolar disorder treatment market with the highest market share
The mood stabilizers segment is expected to dominate the bipolar disorder treatment market due to their crucial role in managing the primary symptoms of the disorder, particularly in stabilizing extreme mood swings. Mood stabilizers, such as lithium, valproate, and lamotrigine, are often considered the cornerstone of bipolar disorder treatment because they effectively control both manic and depressive episodes, preventing frequent relapses. Their ability to maintain mood stability over time is essential in reducing the severity and frequency of mood fluctuations, making them a first-line treatment choice for many patients.
As the most established class of medications for bipolar disorder, mood stabilizers are widely prescribed and have a long track record of efficacy. Despite the emergence of newer treatments, the proven effectiveness and ability to provide long-term symptom control make mood stabilizers an essential part of treatment regimens.
Additionally, ongoing research and development in the mood stabilizer category aim to enhance their effectiveness and minimize side effects, further solidifying their dominant position in the market. For instance, in April 2024, Vanda Pharmaceuticals Inc. (Vanda) announced that the U.S. Food and Drug Administration (FDA) had approved Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
Thus, the mood stabilizers segment is expected to continue leading the bipolar disorder treatment market, driven by their central role in managing the core symptoms of the disorder and their widespread use in clinical practice.
Geographical Analysis
North America is expected to hold a significant position in the global bipolar disorder treatment market with the highest market share
North America is expected to maintain a significant position in the global bipolar disorder treatment market, holding the highest market share, due to several important factors. A large number of individuals suffer from bipolar disorder in the region. For instance, according to the report by Mental Health America, an estimated 2.5% of U.S. adults experience bipolar disorder at some time in their lives. The region has a large number of leading pharmaceutical companies and research institutions that are driving innovation in the development of new and more effective treatments for bipolar disorder.
Ongoing research and the introduction of novel therapies, including mood stabilizers, antipsychotics, and antidepressants, continue to improve patient outcomes and address the challenges of side effects, contributing to the growth of the market. For instance, in February 2025, Teva Pharmaceuticals and Medincell announced FDA acceptance of a supplemental New Drug Application for UZEDY, an extended-release injectable for the maintenance treatment of bipolar I disorder in adults—a milestone reflecting the region’s leadership in bringing novel treatment options to market.
Additionally, there is an increasing focus on mental health awareness across North America, leading to more people seeking diagnosis and treatment for bipolar disorder. This shift, combined with the presence of specialized treatment centers and mental health professionals, ensures that patients have access to comprehensive care. As awareness of mental health issues continues to rise and new treatment options emerge, North America is expected to maintain its dominant position in the bipolar disorder treatment market, driving continued growth and adoption of innovative therapies.
Competitive Landscape
Top companies in the bipolar disorder treatment market include AstraZeneca, AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Intra?Cellular Therapies, Inc. (Johnson & Johnson Services, Inc.), Sanofi, Sun Pharmaceutical Industries Ltd., GSK plc, Novartis AG, Pfizer Inc., among others.
Why Purchase the Report?
- Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
Target Audience 2024
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Disorder Type
2.4. Snippet by Treatment
2.5. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Increased Research and Development (R&D)
3.1.1.2. Growing Focus on Mental Health
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Side Effects of Medications
3.1.2.2. Regulatory Challenges
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Focus on personalized and Targeted Therapies
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. BIPOLAR DISORDER TREATMENT MARKET, BY DISORDER TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
5.1.2. Market Attractiveness Index, By Disorder Type
5.2. Bipolar I Disorder*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Bipolar II Disorder
5.4. Cyclothymic Disorder
5.5. Others
6. BIPOLAR DISORDER TREATMENT MARKET, BY TREATMENT
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
6.1.2. Market Attractiveness Index, By Treatment
6.2. Mood Stabilizers*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Antipsychotics
6.4. Antidepressants
6.5. Antidepressant-antipsychotic Combination
6.6. Antianxiety Medicines
6.7. Electroconvulsive Therapy
6.8. Cognitive Behavioral Therapy (CBT)
6.9. Others
7. BIPOLAR DISORDER TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
7.1.2. Market Attractiveness Index, By Region
7.2. North America
7.2.1. Introduction
7.2.2. Key Region-Specific Dynamics
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.2.5.1. U.S.
7.2.5.2. Canada
7.2.5.3. Mexico
7.3. Europe
7.3.1. Introduction
7.3.2. Key Region-Specific Dynamics
7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.3.5.1. Germany
7.3.5.2. UK
7.3.5.3. France
7.3.5.4. Spain
7.3.5.5. Italy
7.3.5.6. Rest of Europe
7.4. Asia-Pacific
7.4.1. Introduction
7.4.2. Key Region-Specific Dynamics
7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.4.5.1. China
7.4.5.2. India
7.4.5.3. Japan
7.4.5.4. South Korea
7.4.5.5. Rest of Asia-Pacific
7.5. South America
7.5.1. Introduction
7.5.2. Key Region-Specific Dynamics
7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.5.5.1. Brazil
7.5.5.2. Argentina
7.5.5.3. Rest of South America
7.6. Middle East and Africa
7.6.1. Introduction
7.6.2. Key Region-Specific Dynamics
7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
9.1. AstraZeneca*
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue’s
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. AbbVie Inc.
9.3. Otsuka Pharmaceutical Co., Ltd.
9.4. Eli Lilly and Company
9.5. Intra?Cellular Therapies, Inc. (Johnson & Johnson Services, Inc.)
9.6. Sanofi
9.7. Sun Pharmaceutical Industries Ltd.
9.8. GSK plc
9.9. Novartis AG
9.10. Pfizer Inc.
LIST NOT EXHAUSTIVE
10. ASSUMPTIONS AND RESEARCH METHODOLOGY
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Disorder Type
2.4. Snippet by Treatment
2.5. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Increased Research and Development (R&D)
3.1.1.2. Growing Focus on Mental Health
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Side Effects of Medications
3.1.2.2. Regulatory Challenges
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Focus on personalized and Targeted Therapies
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. BIPOLAR DISORDER TREATMENT MARKET, BY DISORDER TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
5.1.2. Market Attractiveness Index, By Disorder Type
5.2. Bipolar I Disorder*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Bipolar II Disorder
5.4. Cyclothymic Disorder
5.5. Others
6. BIPOLAR DISORDER TREATMENT MARKET, BY TREATMENT
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
6.1.2. Market Attractiveness Index, By Treatment
6.2. Mood Stabilizers*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Antipsychotics
6.4. Antidepressants
6.5. Antidepressant-antipsychotic Combination
6.6. Antianxiety Medicines
6.7. Electroconvulsive Therapy
6.8. Cognitive Behavioral Therapy (CBT)
6.9. Others
7. BIPOLAR DISORDER TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
7.1.2. Market Attractiveness Index, By Region
7.2. North America
7.2.1. Introduction
7.2.2. Key Region-Specific Dynamics
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.2.5.1. U.S.
7.2.5.2. Canada
7.2.5.3. Mexico
7.3. Europe
7.3.1. Introduction
7.3.2. Key Region-Specific Dynamics
7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.3.5.1. Germany
7.3.5.2. UK
7.3.5.3. France
7.3.5.4. Spain
7.3.5.5. Italy
7.3.5.6. Rest of Europe
7.4. Asia-Pacific
7.4.1. Introduction
7.4.2. Key Region-Specific Dynamics
7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.4.5.1. China
7.4.5.2. India
7.4.5.3. Japan
7.4.5.4. South Korea
7.4.5.5. Rest of Asia-Pacific
7.5. South America
7.5.1. Introduction
7.5.2. Key Region-Specific Dynamics
7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.5.5.1. Brazil
7.5.5.2. Argentina
7.5.5.3. Rest of South America
7.6. Middle East and Africa
7.6.1. Introduction
7.6.2. Key Region-Specific Dynamics
7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
9.1. AstraZeneca*
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue’s
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. AbbVie Inc.
9.3. Otsuka Pharmaceutical Co., Ltd.
9.4. Eli Lilly and Company
9.5. Intra?Cellular Therapies, Inc. (Johnson & Johnson Services, Inc.)
9.6. Sanofi
9.7. Sun Pharmaceutical Industries Ltd.
9.8. GSK plc
9.9. Novartis AG
9.10. Pfizer Inc.
LIST NOT EXHAUSTIVE
10. ASSUMPTIONS AND RESEARCH METHODOLOGY
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
LIST OF TABLES
Table 1 Global Bipolar Disorder Treatment Market Value, By Disorder Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Bipolar Disorder Treatment Market Value, By Treatment, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Bipolar Disorder Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Bipolar Disorder Treatment Market Value, By Disorder Type, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Bipolar Disorder Treatment Market Value, By Disorder Type, 2022-2033 (US$ Billion)
Table 6 Global Bipolar Disorder Treatment Market Value, By Treatment, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Bipolar Disorder Treatment Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 8 Global Bipolar Disorder Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Bipolar Disorder Treatment Market Value, By Region, 2022-2033 (US$ Billion)
Table 10 North America Bipolar Disorder Treatment Market Value, By Disorder Type, 2022-2033 (US$ Billion)
Table 11 North America Bipolar Disorder Treatment Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 12 North America Bipolar Disorder Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 13 South America Bipolar Disorder Treatment Market Value, By Disorder Type, 2022-2033 (US$ Billion)
Table 14 South America Bipolar Disorder Treatment Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 15 South America Bipolar Disorder Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 16 Europe Bipolar Disorder Treatment Market Value, By Disorder Type, 2022-2033 (US$ Billion)
Table 17 Europe Bipolar Disorder Treatment Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 18 Europe Bipolar Disorder Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 19 Asia-Pacific Bipolar Disorder Treatment Market Value, By Disorder Type, 2022-2033 (US$ Billion)
Table 20 Asia-Pacific Bipolar Disorder Treatment Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Bipolar Disorder Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 22 Middle East and Africa Bipolar Disorder Treatment Market Value, By Disorder Type, 2022-2033 (US$ Billion)
Table 23 Middle East and Africa Bipolar Disorder Treatment Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 24 Middle East and Africa Bipolar Disorder Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 AstraZeneca: Overview
Table 26 AstraZeneca: Product Portfolio
Table 27 AstraZeneca: Key Developments
Table 28 AbbVie Inc.: Overview
Table 29 AbbVie Inc.: Product Portfolio
Table 30 AbbVie Inc.: Key Developments
Table 31 Otsuka Pharmaceutical Co., Ltd.: Overview
Table 32 Otsuka Pharmaceutical Co., Ltd.: Product Portfolio
Table 33 Otsuka Pharmaceutical Co., Ltd.: Key Developments
Table 34 Eli Lilly and Company: Overview
Table 35 Eli Lilly and Company: Product Portfolio
Table 36 Eli Lilly and Company: Key Developments
Table 37 Intra Cellular Therapies, Inc. (Johnson & Johnson Services, Inc.): Overview
Table 38 Intra Cellular Therapies, Inc. (Johnson & Johnson Services, Inc.): Product Portfolio
Table 39 Intra Cellular Therapies, Inc. (Johnson & Johnson Services, Inc.): Key Developments
Table 40 Sanofi: Overview
Table 41 Sanofi: Product Portfolio
Table 42 Sanofi: Key Developments
Table 43 Sun Pharmaceutical Industries Ltd.: Overview
Table 44 Sun Pharmaceutical Industries Ltd.: Product Portfolio
Table 45 Sun Pharmaceutical Industries Ltd.: Key Developments
Table 46 GSK plc: Overview
Table 47 GSK plc: Product Portfolio
Table 48 GSK plc: Key Developments
Table 49 Novartis AG: Overview
Table 50 Novartis AG: Product Portfolio
Table 51 Novartis AG: Key Developments
Table 52 Pfizer Inc.: Overview
Table 53 Pfizer Inc.: Product Portfolio
Table 54 Pfizer Inc.: Key Developments
Table 1 Global Bipolar Disorder Treatment Market Value, By Disorder Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Bipolar Disorder Treatment Market Value, By Treatment, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Bipolar Disorder Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Bipolar Disorder Treatment Market Value, By Disorder Type, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Bipolar Disorder Treatment Market Value, By Disorder Type, 2022-2033 (US$ Billion)
Table 6 Global Bipolar Disorder Treatment Market Value, By Treatment, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Bipolar Disorder Treatment Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 8 Global Bipolar Disorder Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Bipolar Disorder Treatment Market Value, By Region, 2022-2033 (US$ Billion)
Table 10 North America Bipolar Disorder Treatment Market Value, By Disorder Type, 2022-2033 (US$ Billion)
Table 11 North America Bipolar Disorder Treatment Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 12 North America Bipolar Disorder Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 13 South America Bipolar Disorder Treatment Market Value, By Disorder Type, 2022-2033 (US$ Billion)
Table 14 South America Bipolar Disorder Treatment Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 15 South America Bipolar Disorder Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 16 Europe Bipolar Disorder Treatment Market Value, By Disorder Type, 2022-2033 (US$ Billion)
Table 17 Europe Bipolar Disorder Treatment Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 18 Europe Bipolar Disorder Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 19 Asia-Pacific Bipolar Disorder Treatment Market Value, By Disorder Type, 2022-2033 (US$ Billion)
Table 20 Asia-Pacific Bipolar Disorder Treatment Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Bipolar Disorder Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 22 Middle East and Africa Bipolar Disorder Treatment Market Value, By Disorder Type, 2022-2033 (US$ Billion)
Table 23 Middle East and Africa Bipolar Disorder Treatment Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 24 Middle East and Africa Bipolar Disorder Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 AstraZeneca: Overview
Table 26 AstraZeneca: Product Portfolio
Table 27 AstraZeneca: Key Developments
Table 28 AbbVie Inc.: Overview
Table 29 AbbVie Inc.: Product Portfolio
Table 30 AbbVie Inc.: Key Developments
Table 31 Otsuka Pharmaceutical Co., Ltd.: Overview
Table 32 Otsuka Pharmaceutical Co., Ltd.: Product Portfolio
Table 33 Otsuka Pharmaceutical Co., Ltd.: Key Developments
Table 34 Eli Lilly and Company: Overview
Table 35 Eli Lilly and Company: Product Portfolio
Table 36 Eli Lilly and Company: Key Developments
Table 37 Intra Cellular Therapies, Inc. (Johnson & Johnson Services, Inc.): Overview
Table 38 Intra Cellular Therapies, Inc. (Johnson & Johnson Services, Inc.): Product Portfolio
Table 39 Intra Cellular Therapies, Inc. (Johnson & Johnson Services, Inc.): Key Developments
Table 40 Sanofi: Overview
Table 41 Sanofi: Product Portfolio
Table 42 Sanofi: Key Developments
Table 43 Sun Pharmaceutical Industries Ltd.: Overview
Table 44 Sun Pharmaceutical Industries Ltd.: Product Portfolio
Table 45 Sun Pharmaceutical Industries Ltd.: Key Developments
Table 46 GSK plc: Overview
Table 47 GSK plc: Product Portfolio
Table 48 GSK plc: Key Developments
Table 49 Novartis AG: Overview
Table 50 Novartis AG: Product Portfolio
Table 51 Novartis AG: Key Developments
Table 52 Pfizer Inc.: Overview
Table 53 Pfizer Inc.: Product Portfolio
Table 54 Pfizer Inc.: Key Developments
LIST OF FIGURES
Figure 1 Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Bipolar Disorder Treatment Market Share, By Disorder Type, 2024 & 2033 (%)
Figure 3 Global Bipolar Disorder Treatment Market Share, By Treatment, 2024 & 2033 (%)
Figure 4 Global Bipolar Disorder Treatment Market Share, By Region, 2024 & 2033 (%)
Figure 5 Global Bipolar Disorder Treatment Market Y-o-Y Growth, By Disorder Type, 2023-2033 (%)
Figure 6 Bipolar I Disorder Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 7 Bipolar II Disorder Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 8 Cyclothymic Disorder Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 9 Others Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Bipolar Disorder Treatment Market Y-o-Y Growth, By Treatment, 2023-2033 (%)
Figure 11 Mood Stabilizers Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 12 Antipsychotics Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 13 Antidepressants Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 14 Antidepressant-antipsychotic Combination Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 15 Antianxiety Medicines Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 16 Electroconvulsive Therapy Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 17 Cognitive Behavioral Therapy (CBT) Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 18 Other Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 19 Global Bipolar Disorder Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 20 North America Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 21 North America Bipolar Disorder Treatment Market Share, By Disorder Type, 2024 & 2033 (%)
Figure 22 North America Bipolar Disorder Treatment Market Share, By Treatment, 2024 & 2033 (%)
Figure 23 North America Bipolar Disorder Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 24 South America Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 25 South America Bipolar Disorder Treatment Market Share, By Disorder Type, 2024 & 2033 (%)
Figure 26 South America Bipolar Disorder Treatment Market Share, By Treatment, 2024 & 2033 (%)
Figure 27 South America Bipolar Disorder Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 28 Europe Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 29 Europe Bipolar Disorder Treatment Market Share, By Disorder Type, 2024 & 2033 (%)
Figure 30 Europe Bipolar Disorder Treatment Market Share, By Treatment, 2024 & 2033 (%)
Figure 31 Europe Bipolar Disorder Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 32 Asia-Pacific Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 33 Asia-Pacific Bipolar Disorder Treatment Market Share, By Disorder Type, 2024 & 2033 (%)
Figure 34 Asia-Pacific Bipolar Disorder Treatment Market Share, By Treatment, 2024 & 2033 (%)
Figure 35 Asia-Pacific Bipolar Disorder Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 36 Middle East and Africa Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 37 Middle East and Africa Bipolar Disorder Treatment Market Share, By Disorder Type, 2024 & 2033 (%)
Figure 38 Middle East and Africa Bipolar Disorder Treatment Market Share, By Treatment, 2024 & 2033 (%)
Figure 39 AstraZeneca: Financials
Figure 40 AbbVie Inc.: Financials
Figure 41 Otsuka Pharmaceutical Co., Ltd.: Financials
Figure 42 Eli Lilly and Company: Financials
Figure 43 Intra Cellular Therapies, Inc. (Johnson & Johnson Services, Inc.): Financials
Figure 44 Sanofi: Financials
Figure 45 Sun Pharmaceutical Industries Ltd.: Financials
Figure 46 GSK plc: Financials
Figure 47 Novartis AG: Financials
Figure 48 Pfizer Inc.: Financials
Figure 1 Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Bipolar Disorder Treatment Market Share, By Disorder Type, 2024 & 2033 (%)
Figure 3 Global Bipolar Disorder Treatment Market Share, By Treatment, 2024 & 2033 (%)
Figure 4 Global Bipolar Disorder Treatment Market Share, By Region, 2024 & 2033 (%)
Figure 5 Global Bipolar Disorder Treatment Market Y-o-Y Growth, By Disorder Type, 2023-2033 (%)
Figure 6 Bipolar I Disorder Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 7 Bipolar II Disorder Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 8 Cyclothymic Disorder Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 9 Others Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Bipolar Disorder Treatment Market Y-o-Y Growth, By Treatment, 2023-2033 (%)
Figure 11 Mood Stabilizers Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 12 Antipsychotics Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 13 Antidepressants Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 14 Antidepressant-antipsychotic Combination Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 15 Antianxiety Medicines Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 16 Electroconvulsive Therapy Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 17 Cognitive Behavioral Therapy (CBT) Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 18 Other Treatment in Global Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 19 Global Bipolar Disorder Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 20 North America Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 21 North America Bipolar Disorder Treatment Market Share, By Disorder Type, 2024 & 2033 (%)
Figure 22 North America Bipolar Disorder Treatment Market Share, By Treatment, 2024 & 2033 (%)
Figure 23 North America Bipolar Disorder Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 24 South America Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 25 South America Bipolar Disorder Treatment Market Share, By Disorder Type, 2024 & 2033 (%)
Figure 26 South America Bipolar Disorder Treatment Market Share, By Treatment, 2024 & 2033 (%)
Figure 27 South America Bipolar Disorder Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 28 Europe Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 29 Europe Bipolar Disorder Treatment Market Share, By Disorder Type, 2024 & 2033 (%)
Figure 30 Europe Bipolar Disorder Treatment Market Share, By Treatment, 2024 & 2033 (%)
Figure 31 Europe Bipolar Disorder Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 32 Asia-Pacific Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 33 Asia-Pacific Bipolar Disorder Treatment Market Share, By Disorder Type, 2024 & 2033 (%)
Figure 34 Asia-Pacific Bipolar Disorder Treatment Market Share, By Treatment, 2024 & 2033 (%)
Figure 35 Asia-Pacific Bipolar Disorder Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 36 Middle East and Africa Bipolar Disorder Treatment Market Value, 2022-2033 (US$ Billion)
Figure 37 Middle East and Africa Bipolar Disorder Treatment Market Share, By Disorder Type, 2024 & 2033 (%)
Figure 38 Middle East and Africa Bipolar Disorder Treatment Market Share, By Treatment, 2024 & 2033 (%)
Figure 39 AstraZeneca: Financials
Figure 40 AbbVie Inc.: Financials
Figure 41 Otsuka Pharmaceutical Co., Ltd.: Financials
Figure 42 Eli Lilly and Company: Financials
Figure 43 Intra Cellular Therapies, Inc. (Johnson & Johnson Services, Inc.): Financials
Figure 44 Sanofi: Financials
Figure 45 Sun Pharmaceutical Industries Ltd.: Financials
Figure 46 GSK plc: Financials
Figure 47 Novartis AG: Financials
Figure 48 Pfizer Inc.: Financials
